Exhaustion regimes - Interpharma

Leader in research and development

Exhaustion regimes

The legal framework must be developed further to ensure that innovations are adequately protected.

Overview Exhaustion regimes Patents

In patent law, exhaustion refers to the geographical scope of patent protection. National exhaustion means that the protected rights of a product are exhausted in the country in which it is placed on the market, thus making parallel imports illegal. Regional exhaustion enables patented goods to be traded freely within a predetermined economic area, which means that parallel imports are permitted within this area. International exhaustion means that parallel imports are permitted worldwide.

When talking about parallel imports, the term “exhaustion” needs to be understood in the context of rights protected under intellectual property law. Intellectual property law confers on the owner of a product the exclusive right to determine when, in which country, at what price and in what manner they wish to place the product on the market for the first time. These rights are exhausted, i.e. used up, when the owner or someone else with the owner’s permission places the product on the market for the first time. A distinction is made between national and international exhaustion. Under national exhaustion, the protected rights are not affected within the country if the protected product is placed on the market abroad. Parallel imports are not permitted. Under international exhaustion, the owner of the protected rights cannot forbid a parallel import if the protected product was placed on the market abroad. International exhaustion has applied to trademark protection in Switzerland for many years, while patent protection has been governed by unilateral regional exhaustion in the European Economic Area since 2008.

Contrary to popular belief, parallel imports of medicinal products are already possible today in some instances. This is true of medicinal products that are no longer protected by a patent, and these account for a substantial proportion of the pharmaceutical market today. Parallel imports of patented products with prices set by the state are not permitted.

Switzerland goes further than many other countries in allowing some parallel imports. Unrestricted parallel trading is currently possible in a number of emerging economies in Latin America and South East Asia, but no industrialised country has implemented this exhaustion regime. The EU permits parallel imports only within the internal market. In this respect it is closed to third countries, a situation that applies not only to patents but to all intellectual property rights.

Further information

About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2023

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more


Contact us

read more


Latest information and media contacts for media representatives

read more